On October 8th, 2025 Polynoma was acquired by Transcode Therapeutics, Inc. (NASD: RNAZ) Email Format

Biotechnology ResearchCalifornia, United States0-1 Employees

Polynoma LLC is a small biotechnology company based in the San Diego area, concentrating on immuno-oncology research. It is developing seviprotimut-L, a late-stage vaccine candidate intended for adjuvant therapy in melanoma, targeting patients with stage IIB or IIC disease. The product concept relies on a polyvalent shed antigen approach and aims to add an immunotherapy option in the adjuvant setting. In October 2025, Polynoma was acquired by TransCode Therapeutics, Inc., which trades on NASDAQ as RNAZ. The transaction marks a transfer of Polynoma’s program and assets to TransCode Therapeutics.

Sign up for free to view info

Company overview Employee directory